Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.6373 per share.
- Volume: 14 shares.
Material Changes
No material changes to the company's financial position or operations are reported. The filing documents a single acquisition of 14 ordinary shares by Mr. S Dingemans (CFO) on July 14, 2016, executed on the London Stock Exchange. This acquisition resulted from the re-investment of dividends paid to shareholders under the Company's ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is strictly a regulatory disclosure of an insider transaction.
Key Facts for Investor Verification
- Verify the identity of the PDMR: Mr. S Dingemans, CFO.
- Confirm the transaction nature: Dividend re-investment via the ShareReward Plan.
- Note the transaction date: July 14, 2016.
- Observe the transaction size: 14 shares at £16.6373 each.